A US ambulatory-care analysis found more overall cognitive-risk prescribing in dementia visits, but the combined benzodiazepine/Z-drug category looked similar across groups.
What the source reports
Using a nationally representative 2016 visit survey, the investigators examined medications flagged for potential cognitive effects. Overall flagged-medication use was higher in visits involving Alzheimer’s disease or related dementia. Benzodiazepines and Z-drugs together were reported in about 11% of visits in both dementia and non-dementia groups.
Limits and uncertainty
The weighted totals describe visits, not unique patients or directly observed administrations. The overall adjusted association was driven differently across medication categories. Screening does not establish that a drug caused cognitive decline, and a combined category cannot isolate traditional benzodiazepines.
Implications for forensic review
When using this study, preserve both the visit denominator and class-specific results. The overall dementia prescribing estimate should not be assigned to benzodiazepines alone. Individual review requires the medication’s indication, duration, effects, and the patient’s underlying cognitive trajectory.
Source and related reading
Source reviewed: Potentially Inappropriate Medication Use in Older Adults with Alzheimer s Disease and Related Dement (PMC8605947). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Dementia Dental-Sedation Study: Within-Group Change Was Not a Clear Between-Group Effect; NFLIS Benzodiazepine Reports Counted Seized Drug Identifications Rather Than Users.
Leave a Reply